Lazzeri-Barcelo, Francesca
Oliva-Vilarnau, Nuria
Baniol, Marion
Leibiger, Barbara
Bergmann, Olaf http://orcid.org/0000-0003-1065-4107
Lauschke, Volker M. http://orcid.org/0000-0002-1140-6204
Leibiger, Ingo B.
Moruzzi, Noah http://orcid.org/0000-0001-6868-1488
Berggren, Per-Olof
Funding for this research was provided by:
Novo Nordisk Fonden
Knut och Alice Wallenbergs Stiftelse
Ruth och Richard Julins Stiftelse
Ragnar Söderbergs stiftelse
Fondation Leducq
International Foundation for Ethical Research
Zentrum für Regenerative Therapien Dresden
Article History
Received: 31 July 2023
Accepted: 16 January 2024
First Online: 26 January 2024
Competing interests
: P.-O.B. is co-founder and CEO of Biocrine AB, I.B.L. and B.L. are consultants for Biocrine AB. V.M.L. is a co-founder, CEO, and shareholder of HepaPredict AB, as well as a co-founder and shareholder of PersoMedix AB. The remaining authors declare no competing interests.